1. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
No longer a world of 'Prozac' nations? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 5-6
Mark Greener,
Preview
|
|
摘要:
For a while, it seemed that we lived in a world of 'Prozac' nations. The hype surrounding 'Prozac' ['Fluoxetine'] during the 1990s helped combat the stigma associated with depression, and, partly as a result, the number of people diagnosed with the condition increased markedly. In the UK, for example, the number of prescriptions for antidepressants rose from 9 million in 1991 to 22 million in 2000. That meant huge sales of leading antidepressants worldwide [seetable]. But is the bubble about to burst? New research from Datamonitor, an independent market analysis company, revealed that psychiatrists are losing confidence in the clinical effectiveness of leading antidepressants. Datamonitor comments that drug companies need to invest in further research, using outcome measures that reassure physicians and patients that second-generation antidepressants are safe and effective, to take advantage of this huge demand.Table. Breakdown of the global antidepressant market by country 1999-2000
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Anti-D-Rh0 immunoglobulin cost saving in ITP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Lipid-lowering therapy use in The Netherlands |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
OVERTURE: omapatrilat equivalent, but not superior, to enalapril |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 9-10
Ed Susman,
Preview
|
|
摘要:
Eagerly awaited preliminary results from the OVERTURE*study have demonstrated that the experimental vasopeptidase inhibitor omapatrilat ['Vanlev'] is as effective as the ACE inhibitor enalapril ['Vasotec'] in the treatment of moderate-to-severe heart failure. Data presented at a late-breaker symposium at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 2002] showed a 6% reduction in the combined incidence of mortality and hospitalisation for heart failure with omapatrilat, compared with enalapril; the difference was not statistically significant. Furthermore, the incidence of angioneurotic oedema [angioedema], a potentially life-threatening adverse event, was higher in omapatrilat recipients than in patients treated with enalapril. This echoed recently disclosed results from the landmark OCTAVE**study, in which the incidence of angioneurotic oedema was also higher with omapatrilat than with enalapril, when the two drugs were evaluated in patients with hypertension.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Novel dual PPAR agonist improves diabetic parameters |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Estramustine phosphate sodium-based regimen in prostate cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1337,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|